Prevention of pertussis using adenylate cyclase deficient Bordetella strains
AssigneesNational University of Singapore, Institut National De La Sante Et De La Recherche Medicale (Inserm), Institut Pasteur de Lille
InventorsSylvie Claudette Alonso, Annabelle Rui Fen Lim, Camille Locht
Life of this patent
Estimating the term…
Abstract
A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.
Claims10
A vaccine comprising a pharmaceutically acceptable carrier and a live attenuated Bordetella strain that has been rendered deficient in functional adenylate cyclase toxin (CyaA) and functional pertussis toxin (PTX), but retains the ability to colonize a mammalian subject's lungs and induce a protective immune response against Bordetella infection, wherein the genes encoding CyaA, and PTX have been deleted, mutated or replaced.
Dependencies are inferred from the claim text.